Trial · NCT03255096
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 24 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Disease-Free Survival (DFS)- Part 1 and Part 2 | Up to 36 months | |
| Secondary | Overall Survival (OS)- Part 1 and Part 2 | Up to 36 months | |
| Secondary | Half-Life (t1/2) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 | Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) | |
| Secondary | Percentage of Ant-Drug Antibodies (ADA) Against Rituximab - Part 1 and Part 2 | Pre-dose, End of Infusion Day 1 Cycle 1; Pre-dose Day 1 Cycle 2, 3, 4 , 6 and all other even Cycles (Up to 36 months) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03255096/registered?page=2